UNC School of Medicine researchers have led an international clinical trial of patients with generalized myasthenia gravis, finding the therapy is safe and effective across all subtypes.
Nov 6, 2025
0
17
The first-in-class novel human immunoglobulin G1 Fc fragment, efgartigimod, is efficacious and safe for patients with chronic or persistent primary immune thrombocytopenia, according to a study published online Sept. 28 in ...
Oct 6, 2023
0
79
The U.S. Food and Drug Administration has approved Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) subcutaneous injections for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine ...
Jun 28, 2023
0
116
A significant proportion of patients who survive COVID-19 develop a constellation of life-altering symptoms that persist long after the initial infection has resolved. This post-COVID-19 syndrome may result from the development ...
Jun 27, 2023
0
58
Patients taking efgartigimod, a drug being studied for use to treat chronic primary immune thrombocytopenia (ITP), exhibited a significantly greater improvement in platelet counts which are essential to clotting and stopping ...
Dec 10, 2022
0
211
